10/11 Sedative Hypnotic Agents - Pilch Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

sedatives

hyponotics

A

sedative (anxiolytic) agents reduce anxiety and exert a calming effect

hypnotic drugs produce drowsiness and encourage onset/maintenance of sleep state

  • hypnotic effects require more pronounced CNS depression than sedation
  • hypnotic effect can be achieved with some anxiolytic drugs by increasing dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

goals of therapy for GAD (gen anx disorder)

short term

long term

A

short term

  • reduce severity and duration of anx sx
  • improve overall fx

long term

  • remission with minimal or no anx sx
  • no fx impairment
  • incr quality of life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

treatment of GAD

components

factors to consider

  • plan
  • initiating treatment
A

usually comprises psychotherapy and drug therapy

plan depends on:

  • severity/chronicity of sx
  • med history
  • comorbid med/psych conditions

initiation of tx? consider:

  • anticipated adverse effects
  • hx of prior response in pt or family member
  • pt preference

anxiolytic medication indicated for patients experiencing sx severe enough to produce fxnl disability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

short term pharmacotherapy for acute anxiety states

category

examples (7)

similarities/diffs

A

benzodiazepines (BZs) are most effective and commonly prescribed drugs for rapid relief of acute anxiety sx (incl panic attacks)

  • alprazolam (Xanax)
  • chlordiazepoxide (Librium)
  • clonazapam (Klonopin)
  • clorazepate (tranxene)
  • diazepam (Valium)
  • lorazepam (Ativan)
  • oxazepam (Serax)

similarities: all effective as anxiolytics

differences: PK!

  • need to consider PK and clinical situation to choose most effective agent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

benzodiazepines

PK

A

absorption: v good at crossing bbb! …but also crosses barriers you might not want

lipophilicity is major determinant of rate at which a BZ enters the CNS

  • cross placental barrier → can contribute to depression of neonatal vital fx if administered pre-delivery
  • detectable in breastmilk → may exert depressant effects in nursing infant

elimination

clearance generally reduced in elderly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

midazolam

peaks at .4-.8 hr

half life 1-7 hr

use?

why not GAD?

A

useful for procedural sedation!

  • quick onset, will wear off soon after procedure

BUT

not so good for GAD because wears off too quick!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

why do some drugs have longer half-lives?

what is the effect of multiple doses?

A

BZs for which parent drug AND metabolites are active tend to have long half-life

  • more likely to have cumulative effects (ex. drowsiness) with multiple doses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

benzodiazepines

pharmacodynamics

site of action

mechanism of action

A

BZ are GABA-ergic (potentiates action of GABA at GABAa receptor) → enhance inhibition!

GABAa receptor : Cl ion channel

  • heteropentameric glycoprotein assembled from 5 subunits
  • major isoform in brain is (alpha1)2(beta2)2(gamma2)
  • activated by GABA (gamma-aminobutyric acid)
    • GABA binds at 2 sites between alpha and beta subunits → channel opening → hyperpol → inhibition

BZ mechanism of action: bind to single site between alpha and gamma subunits → increase freqency of GABA-gated channel openings

  • same site targeted by flumazenil (BZ antagonist), zolpidem/zaleplon/eszopiclone (hypnotics)
  • NOT targeted by barbiturates!

overall effect:

  • potentiate Cl ion channel effects of GABA
  • potentiate GABAergic inhibition at all levels of neuraxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

BZ advantages / disadvantages

A

advantages

  • rapid onset of action
  • relatively high therapeutic index AND availability of flumazenil (for OD, if required)
  • low risk of drug interactions based on liver enzyme induction
  • minimal effects on CV and autonomic fx

disadvantages

  • risk of dependence/addiction
  • depression of CNS fx
  • amnesic effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

BZ dosing considerations

A

general principle: want minimum dose possible for the shortest period of time

  • want a dose that does not impair mentation or motor functions

specifics

  • rx should be written for short periods (2-4wk) bc little justification for longer term tx
  • elderly? → approx half doses are safer, usually effective
  • combination with other anti-anx agents, antihistamines, anticholinergics, ethanol should be avoided
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

BZ toxic effects

A
  1. anxiolytic doses → drowsiness, impaired judgment, diminished motor skills (can impact driving, job perf, personal relationships)
  • overuse is a common cause of confusional state in elderly
  • high dose → toxicity presenting as lethargy or state of exhaustion or gross sx of ethanol intox (behavioral inhibition)
  1. can cause significant dose-related anterograde amnesia and significantly impair ability to learn new info
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

BZ

tolerance, psychologic dependence, physiologic dependende

A

all potential results of prolonged use of BZ

  • after extended use, abrupt cessation → withdrawal sx (states of incr anx, insomnia, CNS excitability)
    • BZ with longer half-life is eliminated more slowly → cause less severe withdrawal signs
  • to avoid withdrawal sx…taper doses slowly over weeks!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

BZ toxicity:

ODs

A

dedative-hypnotics are durgs most frequently involved in deliberate OD!

severe toxicity: respiratory depression complicated by aspiration of gastric contents (more likely if ethanol present)

good news → even after v high dose ingenstion, outcome is rarely fatal if discovered early and conservative tx regimen started

  • ensure patent airway (ventilate if necessary), maintain plasma volume, renal output, cardiac fx
  • rapid reversal agent: flumazenil
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

flumazenil

A

synthetic BZ derivative used to

  • reverse CNS depressant effects of BZ OD
  • hasten recovery after BZ use in medical procedures

mechanism: competitive inhibitor of BZ on GABAa receptors

  • antagonizes actions of BZ and zolpidem, zaleplon, eszopiclone, but not barbiturates → i.e. ANY GABA-ERGIC DRUGS!

IV flumazenil acts rapidly, but with short half-life (0.7-1.3hr)

  • rapid action: so fast it can precipitate withdrawal
  • short half-life: all BZs have longer duration of action than flumazenil → sedation commonly recurs → repeated admin is required
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

long term pharmacotx for GAD

classes

examples

how do they work?

A

considered first-line drugs in chronic management of GAD, esp in presence of depressive sx

selective serotonin reuptake inhibitors (SSRIs)

  • escitalopram (Lexapro)
  • paroxetine (Paxil)
  • sertraline (Zoloft)
  • fluoxetine (Prozac)

serotonin-norepinephrine reuptake inhibitors (SNRIs)

  • duloxetine (Cymbalta)
  • venlafaxine (Effexor)

anti-anx response of antideps requires 2-4wk or longer!

how do they work?

potentially reduce somatic anxiety symptoms by activating stress-adapting neuronal pathways

  • not reducing activation (like BZ)
  • instead, activating pathways for coping!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

buspirone (BuSpar)

A

has selective anxiolytic effects without causing marked sedative, hypnotic, euphoric effects

  • NOT GABA-ergic → low risk of dependence, low tolerance, can be taken chronically
  • takes 2 weeks or longer → NOT suitable for acute anx states

mechanism: believed to be through…

  • partial agonist activity at 5-HT1a receptors
  • affinity for brain dopamine D2 receptors

considered second-line agent bc of inconsistent reports of long-term efficacy and lack of efficacy for other potential concurrent depressive disorders

17
Q

buspirone toxicity

A

better toxicological profile than BZs or antidepressants!

adverse rxns: nausea, abd pain, drowsiness, dizziness

  • typically transient

drug interactions → interacts with CPY3A4 :(

  • inducers and inhibitors of CYP3A4
  • MAO inhibitors → can result in elevated bp
18
Q

hypnotics

categories

examples

A

drugs used for tx of insomnia

GABAergic drugs

1. benzodiazepines

  • triazolam (Halcion)
  • temazepam (Restoril)
  • estazolam (ProSom)
  • flurazepam (Dalmane)
  • quazepam (Doral)

2. non-BZ hypnotics

  • zaleplon (Sonata)
  • zolpidem (Ambien)
  • eszopiclone (Lunesta)

*. new non-GABAergic hypnotics

  • ramleteon (Rozerem)
  • suvorexant (Belsomra)
19
Q

hypnotics goal of tx

A
  • correct underlying sleep complaint
  • consolidate sleep
  • improve daytime fx
  • avoid adverse effects

same principle holds: wants lowest possible dose for shortest possible time to be effective

20
Q

GABAergic drugs used as hypnotic agends

A

most commonly used drugs for insomnia

1. benzodiazepines

  • hypnotic doses are higher than anxiolytic doses → effects
    • incr total sleep time
    • decr sleep latency (time to fal asleep) and awakenings
  • prolonged use at hypnotic dose? dependency!
    • cessation → withdrawal! and associated rebound insomnia :(

2. non-BZ hypnotics (zolpidem, zaleplon, eszopiclone)

  • bind to same GABAa site as BZs (more selective → only hit alpha1 subunits)
  • effects
    • decrease time to persistent sleep
    • zolpidem/eszopiclone → incr total sleep time
      • zaleplon does not incr total sleep time
  • risk of dependency!!! not recommended for long-term use
    • abrupt cessation → withdrawal sx (less severe than BZ) and rebound insomnia (zolpidem and zaleplon at high doses)
  • favorable clinical features: rapid onset of activity, short half-lives, modest day-after psychomotor depression, few amnesic effects
    • unlike some BZs, no anticonvulsant and muscle-relax activities
21
Q

hypnotic agents : benzodiazepines

effects

dependency risk

A

1. benzodiazepines

  • hypnotic doses are higher than anxiolytic doses → effects
    • incr total sleep time
    • decr sleep latency (time to fal asleep) and awakenings
  • prolonged use at hypnotic dose? dependency!
    • cessation → withdrawal! and associated rebound insomnia :(
22
Q

hypnotics: non-BZ GABAergics

mech of action

effects

dependency risk

favorable ft

diff from BZ

A

2. non-BZ hypnotics (zolpidem, zaleplon, eszopiclone)

  • bind to same GABAa site as BZs (more selective → only hit alpha1 subunits)
  • effects
    • decrease time to persistent sleep
    • zolpidem/eszopiclone → incr total sleep time
      • zaleplon does not incr total sleep time
  • risk of dependency!!! not recommended for long-term use
    • abrupt cessation → withdrawal sx (less severe than BZ) and rebound insomnia (zolpidem and zaleplon at high doses)
  • favorable clinical features: rapid onset of activity, short half-lives, modest day-after psychomotor depression, few amnesic effects
    • ​short half-life means you recover from them quicker

major diffs from BZ:

  • shorter half lives
  • ​unlike some BZs, no anticonvulsant and muscle-relax activities
23
Q

non-GABAergic hypnotics

ramelteon (Rozerem)

mech

effects

adv effects

A

new nonGABAergic hypnotic

mechanism:

  • agonist at MT1 and MT2 receptors in brain
    • MT receptors thought to be involved in maintaining circadian rhythm underlying sleep-wake cycle
  • has NO GABAergic effects in CNS

effects:

  • decr sleep latency
  • increases sleep periods
  • NO rebound insomnia, NO risk of dependence
  • effective for treatment of sleep apnea too

common adv effects: dizziness, headache, somnolence

caveat: not as effective as the z-drugs

24
Q

non-GABAergic hypnotics

suvorexant (Belsomra)

mech

effects

adv effects

A

new nonGABAergic hypnotic

mechanism:

  • antagonist at orexin receptors in brain
    • orexin is an nt in the wakefulness pathway → central promoter of wakefulness
  • has NO GABAergic effects in CNS

effects:

  • decr sleep latency
  • increases sleep periods
  • associated with risk of abuse or dependence (controlled sub)

common adv effects: day-after somnolence, headache, dizziness

  • can cause “sleep-driving” behavior, amnesic effects